Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1+ NSCLC"

90 views
November 24, 2023
Comments 0
Login to view comments. Click here to Login